FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,385,771 | -53.3% | 137,341 | +3.6% | 0.00% | -60.0% |
| Q3 2022 | $2,970,000 | +87.6% | 132,552 | +107.5% | 0.01% | +150.0% |
| Q2 2022 | $1,583,000 | -36.8% | 63,879 | +1.6% | 0.00% | -33.3% |
| Q1 2022 | $2,506,000 | -9.6% | 62,881 | +32.7% | 0.00% | -25.0% |
| Q4 2021 | $2,773,000 | +44.2% | 47,388 | +46.1% | 0.00% | +33.3% |
| Q3 2021 | $1,923,000 | -62.6% | 32,440 | -45.2% | 0.00% | -50.0% |
| Q2 2021 | $5,141,000 | +38.5% | 59,234 | +31.6% | 0.01% | +20.0% |
| Q1 2021 | $3,711,000 | -73.8% | 45,008 | -71.1% | 0.01% | -50.0% |
| Q4 2020 | $14,176,000 | +323.4% | 155,902 | +77.3% | 0.01% | +100.0% |
| Q3 2020 | $3,348,000 | +21.4% | 87,908 | +9.4% | 0.01% | 0.0% |
| Q2 2020 | $2,758,000 | +19.6% | 80,389 | -13.6% | 0.01% | 0.0% |
| Q1 2020 | $2,306,000 | +27.4% | 93,003 | +0.5% | 0.01% | +66.7% |
| Q4 2019 | $1,810,000 | – | 92,503 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |